Program
PN20
A development code.
Its studies are mostly in Thrombocytopenia · Purpura, Thrombocytopenic, Idiopathic, led by Chongqing Peg-Bio Biopharm.
Furthest: phase 2, since Feb 26, 20263 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Peg-Bio Biopharm | 30 open or running | phase 2since Feb 26, 2026 | Jul 18, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 18, 2024First studies: 2 phase 1 studiesFirst studyNCT06521931, NCT06523088
- Feb 26, 2026Phase 2 study in ThrombocytopeniaPhase 2 reachedNCT07446491 · 54 enrolled · China
- Oct 22, 2026Primary completion moved from 2026-05-30 to 2026-10-10Date moved laterphase 2 · +4 months · NCT07446491
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07446491Thrombocytopenia · China | 2 | Completed | Oct 10, 2026 | 54 |
| NCT06523088Purpura, Thrombocytopenic, Idiopathic · China | 1 | Completed | Jan 5, 2023 | 27 |
| NCT06521931Thrombocytopenia · China | 1 | Completed | Jan 13, 2025 | 24 |
How it is read
Names in the registry
- “PN20”, 3 entries
Codes read as this program: PN20.
Conditions, from the studies’ own filings
- Thrombocytopenia, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.